IOM prioritizes OTC contraceptive, supplement research
This article was originally published in The Tan Sheet
Executive Summary
An Institute of Medicine 1report to Congress on priority topics for comparative effectiveness research lists research on "innovative strategies for preventing unintended pregnancies" - including OTC access to oral contraceptives and other hormonal methods - as a top-tier priority. Lower-level items in the inventory of 100 priorities include comparing the effectiveness of dietary supplements in treating prevalent conditions, smoking-cessation strategies in minority and adolescent populations, and consumer self-care in avoiding early morbidity among people with mental illness. IOM submitted the report June 30 as required by the American Recovery and Reinvestment Act of 2009. The law charged IOM with recommending projects the Department of Health and Human Services should fund with the $1.1 billion allocated for CER (2"The Tan Sheet" March 16, 2009)
You may also be interested in...
Baucus Maintains Public/Private Comparative Effectiveness Vision
Senate Finance Committee Chairman Max Baucus continues planning to include comparative effectiveness in the health care reform debate, even with research funding included in the American Recovery and Reinvestment Act
‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.